FDA Grants Frontline Eltrombopag Breakthrough Designation for Severe Aplastic Anemia

January 4, 2018 – The FDA has granted a breakthrough therapy designation to eltrombopag for use in combination with standard immunosuppressive therapy as a first-line treatment for patients with severe aplastic anemia (SAA). The small molecule thrombopoietin receptor agonist is already approved in the United State for the treatment of patients with SAA who have had an insufficient response to immunosuppressive therapy. The breakthrough designation will … (leggi tutto)